American Society of Hirudotherapy

W. pigra cDNA Clone Library (Multi-Anticoagulant)

Early W. pigra anticoagulant cDNA clones with hementin-like / saratin-like activities, compiled by Tang 2020.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Expert consensus
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

cDNA-clone-level identification does NOT establish clinical efficacy. No FDA-approved derivative; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Source species
Whitmania pigra
Discovered
2020 · Tang X et al.

Biological Targets

  • → thrombin; platelet aggregation; fibrinolysis enhancement (composite)

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.